Tirzepatide Dosage Guide for Research
This guide provides researchers with comprehensive dosage reference information for tirzepatide, the dual GIP/GLP-1 receptor agonist. All dosing data is derived from published clinical trial protocols, primarily the SURMOUNT and SURPASS trial programs.
Standard Titration Schedule
The SURMOUNT/SURPASS titration protocol follows a 4-week dose-escalation schedule:
| Week | Dose | Duration | Purpose |
|---|---|---|---|
| 1-4 | 2.5 mg | 4 weeks | Initiation |
| 5-8 | 5.0 mg | 4 weeks | Escalation 1 |
| 9-12 | 7.5 mg | 4 weeks | Escalation 2 |
| 13-16 | 10.0 mg | 4 weeks | Escalation 3 |
| 17+ | 15.0 mg | Maintenance | Target dose |
Note: In clinical trials, three target maintenance doses were studied: 5mg, 10mg, and 15mg. The titration continues until the assigned target dose is reached.
Reconstitution Guide
Lyophilized tirzepatide requires reconstitution with bacteriostatic water before use.
Concentration Table (5mg Vial)
| BAC Water | Concentration | 2.5mg Dose | 5mg Dose |
|---|---|---|---|
| 1.0 mL | 5.0 mg/mL | 50 units | 100 units (full syringe) |
| 2.0 mL | 2.5 mg/mL | 100 units | N/A (exceeds syringe) |
Concentration Table (10mg Vial)
| BAC Water | Concentration | 2.5mg | 5mg | 7.5mg | 10mg |
|---|---|---|---|---|---|
| 1.0 mL | 10 mg/mL | 25 units | 50 units | 75 units | 100 units |
| 2.0 mL | 5.0 mg/mL | 50 units | 100 units | N/A | N/A |
Concentration Table (15mg Vial)
| BAC Water | Concentration | 5mg | 10mg | 15mg |
|---|---|---|---|---|
| 1.5 mL | 10 mg/mL | 50 units | 100 units | N/A |
| 3.0 mL | 5.0 mg/mL | 100 units | N/A | N/A |
Clinical Trial Results by Dose
Weight Reduction (SURMOUNT-1, 72 weeks)
| Dose | Mean Weight Loss | ?5% Loss | ?10% Loss | ?20% Loss |
|---|---|---|---|---|
| 5 mg | -15.0% | 85% | 69% | 32% |
| 10 mg | -19.5% | 89% | 79% | 46% |
| 15 mg | -20.9% | 91% | 84% | 57% |
| Placebo | -3.1% | 35% | 14% | 1.5% |
HbA1c Reduction (SURPASS-2, 40 weeks)
| Dose | HbA1c Reduction | vs Semaglutide 1mg |
|---|---|---|
| 5 mg | -2.01% | Superior |
| 10 mg | -2.24% | Superior |
| 15 mg | -2.37% | Superior |
| Semaglutide 1mg | -1.86% | — |
Pharmacokinetic Parameters
- Half-life: ~5 days (120 hours)
- Tmax: 8-72 hours post-injection
- Steady state: Reached after 4 weeks of weekly dosing
- Route: Subcutaneous injection (abdomen, thigh, or upper arm)
- Administration: Once weekly, any time of day, regardless of meals
Dose Calculation Formula
Volume (mL) = Desired Dose (mg) ÷ Concentration (mg/mL)
Example: For a 7.5mg dose from a 10mg/mL solution:
7.5 ÷ 10 = 0.75 mL = 75 units on an insulin syringe
See our complete dosage calculation guide and reconstitution guide for step-by-step instructions.
Comparison with Semaglutide Dosing
| Parameter | Tirzepatide | Semaglutide |
|---|---|---|
| Starting dose | 2.5 mg/week | 0.25 mg/week |
| Max research dose | 15 mg/week | 2.4 mg/week |
| Titration period | 16 weeks | 16 weeks |
| Half-life | ~5 days | ~7 days |
| Frequency | Once weekly | Once weekly |
For a full comparison, see semaglutide vs tirzepatide.
Frequently Asked Questions
What is the highest dose of tirzepatide studied?
15mg once weekly is the highest dose used in Phase 3 clinical trials (SURMOUNT and SURPASS programs).
Can the titration be slowed down?
Yes. Some protocols extend the escalation period at each dose if tolerability is a concern. Each dose level can be maintained for longer than 4 weeks before escalating.
What is the most common side effect limiting dose escalation?
Nausea is the most frequently reported dose-limiting side effect, occurring in 12-33% of participants across dose levels in SURMOUNT trials. It typically peaks during dose escalation and diminishes during maintenance.
Related Articles
- What is Tirzepatide?
- Tirzepatide: Complete Research Guide
- Semaglutide Dosage Chart
- Semaglutide vs Tirzepatide
All products sold by Proxiva Labs are intended for research and laboratory use only. Not for human consumption.